Effect of oral tolvaptan for 1 year in patients with functional mitral regurgitation
| Autor: | Hirofumi Hioki, Fukuko Nagura, Naoyuki Yokoyama, Kiyoko Uno, Masanari Kuwabara, Ruri Ishibashi, Yusuke Watanabe, Ken Kozuma, Miho Mitsui, Akihisa Kataoka |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Tolvaptan Inverse probability of treatment weighting Internal medicine medicine Clinical endpoint Humans In patient Diuretics Functional mitral regurgitation Aged Aged 80 and over Heart Failure business.industry Mitral Valve Insufficiency Vascular surgery Benzazepines medicine.disease Cardiac surgery Hospitalization Treatment Outcome Heart failure Cardiology Female Cardiology and Cardiovascular Medicine business Antidiuretic Hormone Receptor Antagonists medicine.drug |
| Zdroj: | Heart and vessels. 37(3) |
| ISSN: | 1615-2573 |
| Popis: | The effect of the oral selective vasopressin V2-receptor antagonist tolvaptan for chronic phase therapy on patients with FMR remains unclear. We aimed to determine the efficacy of oral tolvaptan in patients with significant functional mitral regurgitation (FMR) to reduce the mortality and rehospitalization due to worsening heart failure (HF). We enrolled 219 patients (mean age 76 ± 9 years, 59.4% men) who were admitted at our hospital due to congestive HF during different two 1-year periods. The patients were divided into 2 groups: those who had significant FMR (MR ≥ grade 2 [n = 76]) and those who did not (MR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink